Ro 63-0563 [4-amino-N-(2,6 bis-methylamino-pyridin-4-yl)-benzene sulfonamide] is a high affinity 5-hydroxytryptamine 6 (HT 6 ) receptor antagonist with more than 100-fold selectivity for the 5-HT 6 receptor compared with 69 other receptors and binding sites. The present study describes the properties of The effects of the neurotransmitter serotonin (5-HT) are
lisuride Ͼ ergotamine ϳ Ro 04 -6790 Ͼ 5-HT Ͼ amitriptyline ϳ metergoline ϳ mianserin ϳ ritanserin Ͼ methysergide Ͼ mesulergine) was similar to that obtained by using either 6 receptor ligands at this binding site were similar to those found for the recombinant rat and human 5-HT 6 receptor, which suggested the presence of 5-HT 6 receptors in porcine striatum.
The effects of the neurotransmitter serotonin (5-HT) are mediated by at least 14 different receptors: one ligand-gated ion channel (the 5-HT 3 receptor) and 13 G protein-coupled receptors (Boess and Martin, 1994; Hoyer and Martin, 1997) . Of these, at least five are coupled to inhibition of adenylyl cyclase (5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , 5-HT 1F ), three are linked to phosphoinositide hydrolysis (5-HT 2A , 5-HT 2B , 5-HT 2C ), and three have been shown to stimulate adenylyl cyclase activity (5-HT 4 , 5-HT 6 , 5-HT 7 ). Unlike the classical 5-HT receptors, the 5-HT 6 receptor was not recognized as a pharmacological entity in physiological or radioligand binding experiments before its cloning from rat striatal cDNA (Monsma et al., 1993; Ruat et al., 1993) . The highest levels of 5-HT 6 receptor mRNA were detected in the olfactory tubercle, nucleus accumbens, striatum, and hippocampus (Monsma et al., 1993; Ruat et al., 1993; Ward et al., 1995; Gérard et al., 1996) . To determine the distribution of 5-HT 6 receptor protein, Gérard et al. (1997) raised polyclonal antibodies against a synthetic peptide corresponding to part of the carboxyl-terminal domain of the 5-HT 6 receptor. They observed high levels of 5-HT 6 receptor-like immunoreactivity in olfactory tubercle, piriform cortex, nucleus accumbens, islands of Calleja, striatum, hippocampus (CA1 and dentate gyrus), and the molecular layer of the cerebellum.
Many nonselective compounds, including several tricyclic antidepressant drugs, antipsychotic agents, and tryptamine and ergoline derivatives interact with the 5-HT 6 receptor, as was shown in binding studies on recombinant rat and human receptors using [ 3 H]LSD, 125 I-LSD, and [ 3 H]5-HT as radioligands (Monsma et al., 1993; Roth et al., 1994; Boess et al., 1997; reviewed in Sleight et al., 1997) .
Putative 5-HT 6 -like receptors positively coupled to adenylyl cyclase have been described in the mouse neuroblastomaderived cell lines N18TG2 and NCB20 (Berry-Kravis and Dawson, 1983; Conner and Mansour, 1990; Unsworth and Molinoff, 1994) . In addition, responses with a 5-HT 6 receptorlike profile have been observed in pig caudate membranes (Schoeffter and Waeber, 1994) and in mouse embryonic striatal neurons (Sebben et al., 1994) .
Until recently, the physiological role of the 5-HT 6 receptor was not known, because of the lack of selective ligands. However, the functional significance of this receptor has been investigated by using intracerebroventricular injections of 5-HT 6 receptor-specific antisense oligonucleotides. This treatment, which should abolish or reduce the expression of 5-HT 6 receptor protein, produced a behavioral syndrome consisting of yawning, stretching, and chewing (Bourson et al., 1995; Sleight et al., 1996) . Recently, we have described two selective 5-HT 6 receptor antagonists, Ro 04 -6790 and Ro 63-0563, and demonstrated the ability of Ro 04 -6790 to produce behavioral effects similar to those observed after antisense treatment (Sleight et al., 1998 ). In the current study, we present the first selective 5-HT 6 receptor radioligand [
3 H]Ro 63-0563 and demonstrate that it labels recombinant rat and human 5-HT 6 receptors as well as 5-HT 6 receptor binding sites in rat and porcine striatal membranes.
Experimental Procedures
Materials. HeLa cells expressing human 5-HT 6 receptors were obtained from Dr. David Sibley (National Institutes of Health, Bethesda, MD) under licensing agreement. 5-HT was purchased from Fluka (Buchs, Switzerland); ergotamine from Sigma (Buchs, Switzerland); mesulergine, metergoline, methysergide, lisuride, methiothepin, clozapine, amitriptyline, ritanserin, mianserin, and pargyline from Research Biochemicals (Natick, MA). Dulbecco's modified Eagle's medium, fetal bovine serum, penicillin, streptomycin, and geneticin were obtained from Gibco Life Technologies (Basel, Switzerland). Ro 20-1724, Ro 63-0563 ( Fig. 1) , Ro 04-6790 (Fig. 1) , and LSD were synthesized at F. Hoffmann-La Roche AG (Basel, Switzerland). [
3 H]Ro 63-0563 (specific activity, 29 Ci/mmol) was kindly prepared by Dr. Philipp Huguenin at F. Hoffmann-La Roche (Basel).
Preparation of membranes from cells expressing recombinant 5-HT 6 receptor. Membranes were prepared from HEK 293 cells stably transfected with the rat 5-HT 6 receptor or HeLa cells stably expressing a human 5-HT 6 receptor clone (Kohen et al., 1996) . HEK 293 cells were grown in Dulbecco's modified Eagle medium ϩ 10% fetal bovine serum containing penicillin (100 IU/ml), streptomycin (100 g/ml), and 0.5 mg/ml geneticin in a humidified atmosphere (5% CO 2 ). HeLa cells were grown in exactly the same conditions except that geneticin was omitted from the media. The cells were detached with phosphate-buffered saline containing 1 mM EDTA, washed with phosphate-buffered saline (Gibco Life Technologies) by two centrifugations (10 min, 500 ϫ g) and the resulting pellet was resuspended in ice-cold 50 mM Tris⅐HCl, pH 7.4, containing 10 mM MgCl 2 and 0.5 mM EDTA by using a Polytron homogenizer (15 sec at maximal speed) at a concentration corresponding to 2 ϫ 10 6 cells/ml. This homogenate was centrifuged at 100,000 ϫ g for 60 min, the resulting pellet was resuspended in the same buffer to obtain a concentration corresponding to 4 ϫ 10 7 cells/ml, and aliquots were stored at Ϫ80°. Preparation of rat and porcine striatal membranes. Before dissection, rat brains (male Ibm:RoRo; Biological Research Laboratories, Fü llinsdorf, Switzerland) and porcine brains (from a local abattoir) were kept on ice. Striatal tissue (in 3-g aliquots) was homogenized in 26 ml of 0.32 M sucrose with a glass/teflon homogenizer and centrifuged for 10 min at 1000 ϫ g (4°). The pellet was discarded and the supernatant centrifuged for 30 min at 25,000 ϫ g. The pellet was resuspended in 26 ml of 50 mM Tris⅐HCl, pH 7.4, centrifuged for 15 min at 25,000 ϫ g, resuspended in 50 mM Tris⅐HCl, incubated for 15 min at 37°and centrifuged for 15 min at 25,000 ϫ g. The pellet was washed two times by resuspension in 50 mM Tris⅐HCl and centrifugation for 15 min at 25,000 ϫ g and the final pellet was stored frozen at Ϫ80°. For binding experiments with rat and porcine striatal membranes, the pellets were resuspended in 26 ml of assay buffer. Binding assays were performed using 0.5 ml of the membrane suspension (corresponding to 1.5 mg of protein per assay tube) in a final assay volume of 1 ml using a shaking incubator. Otherwise, the assay conditions and the ligand concentrations examined were similar to the experiments with recombinant 5-HT 6 receptors with the exception of the final concentration of [ 3 H]Ro 63-0563 used in the competition and kinetic experiments (2 nM). At this concentration, specific binding corresponded to 20% of total binding.
The incubations were terminated by rapid filtration through Whatmann GF/B filters pretreated with polyethyleneimine (0.3%). The filters were washed with 3 ϫ 2 ml of cold Tris⅐HCl (50 mM, pH 7.4) and the radioactivity retained on the filters was measured by liquid scintillation counting in 2 ml of scintillation fluid. All experiments were performed in triplicate and repeated at least three times (unless indicated otherwise). Values are given as mean Ϯ standard error. Data were analyzed using the programs EBDA and LIGAND (Munson and Rodbard, 1980; McPherson, 1985) . Protein concentrations were determined using either the bicinchoninic acid method (Pierce, Munich, Germany) or a Coomassie Brilliant Blue G-250 based assay (Biorad). binding to the recombinant rat 5-HT 6 receptor (methiothepin Ͼ LSD Ͼ clozapine Ͼ lisuride Ͼ ergotamine Ͼ 5-HT Ͼ amitriptyline ϳ metergoline ϳ mianserin ϳ ritanserin Ͼ methysergide Ͼ mesulergine) was similar to that determined with [ 3 H]LSD using the same cells (Table 1 ). The Hill slopes of both antagonists (e.g., methiothepin, clozapine, mianserin, ritanserin) and agonists (e.g., 5-HT, LSD, lisuride), as well as those of unlabeled Ro 63-0563 and the structurally related 5-HT 6 receptor-selective antagonist Ro 04-6790, were close to one and competition curves with 14 ligand concentrations did not suggest the presence of multiple binding sites (Fig. 5) .
Results
The affinities of the ligands tested at the human 5-HT 6 receptor were very similar to those determined for the recombinant rat 5-HT 6 receptor (correlation coefficient r ϭ 0.97, 14 experiments) ( Fig. 9 ).
Discussion
Ro 63-0563 is a high affinity 5-HT 6 receptor antagonist with more than 100-fold selectivity for the 5-HT 6 receptor compared with 69 other receptors and binding sites (Sleight et al., 1998 . This suggests that these radioligands do not distinguish between different agonist high and low affinity states of the recombinant rat 5-HT 6 receptor expressed in HEK 293 cells.
The pharmacological profile of the rat 5-HT 6 receptor labeled with [ .
Because Northern blots (Monsma et al., 1993) , in situ hybridization (Ward et al., 1995) , and reverse-transcription polymerase chain reaction (Gérard et al., 1996) had demonstrated especially high levels of 5-HT 6 receptor mRNA in the rat striatum and high levels of 5-HT 6 receptor-like immunoreactivity had also been observed in this brain region (Gérard et al., 1997) 3 H]Ro 63-0563) with the values determined for the recombinant rat 5-HT 6 receptor showed a significant correlation (r ϭ 0.9, six experiments, p Ͻ 0.01) suggesting that this [ 3 H]Ro 63-0563 binding site actually corresponds to the native rat 5-HT 6 receptor. Because of the relatively large quantity of tissue needed per assay, a more detailed pharmacological characterization was carried out using porcine striatal membranes, a tissue in which 5-HT-mediated stimulation of adenylyl cyclase activity with a 5-HT 6 receptor-like profile has been reported (Schoeffter and Waeber, 1994) . The amount of specific binding observed in porcine striatal membranes (20 -30%) was generally higher than that measured with rat striatal membranes (10 -20%), which facilitated a more detailed characterization of the [ 3 H]Ro 63-0563 binding in the porcine tissue. We did attempt to improve the level of specific binding by changing pH, the buffer used for the binding assay (HEPES instead of Tris), and the concentrations of the various salts in the incubation buffer. None of these changes, however, significantly improved specific binding (results not shown). In equilibrium binding studies values of the 5-HT 6 receptor ligands tested at the [ 3 H]Ro 63-0563 binding site in porcine striatal membranes showed a statistically significant correlation with the values measured for both rat (correlation coefficient r ϭ 0.76, 14 experiments, p Ͻ 0.01) and human recombinant 5-HT 6 receptor (r ϭ 0.78, 14 experiments, p Ͻ 0.01). Although the overall pharmacological profile was quite similar to that of the rat and human receptor, methiothepin, clozapine, and amitriptyline had about 10-fold lower affinity for the binding site in porcine brain. This is in agreement with the low pK b values of methiothepin and clozapine for the inhibition of 5-HT mediated stimulation of adenylyl cyclase in porcine striatal membranes reported by Schoeffter and Waeber (1994) . High concentrations of all ligands tested displaced . Guanylyl imidodiphosphate had no effect on either the amount of specific binding, the affinity of 5-HT, or the Hill slope of the displacement (results not shown).
We have previously demonstrated that the apparent affinity of certain compounds, particularly tryptamine derivatives, was dependent upon whether [
3 H]5-HT or [ 3 H]LSD was used as the radioligand . Because the purpose of the present study was to determine whether 5-HT 6 receptors are expressed in the rat and porcine striatum, we specifically chose ligands that had consistent affinities with respect to both (Glatt et al., 1995) . However, 5-HT displayed a very low affinity (K i ϭ 200,000 nM) for this [ 3 H]clozapine binding site in rat brain compared with an affinity of 150 nM at recombinant rat 5-HT 6 receptors (Glatt et al., 1995) , which suggests that these binding sites may not correspond to the 5-HT 6 receptor, but to a distinct receptor with similar pharmacological properties. In contrast, 5-HT has a high affinity for both the recombinant rat and human 5-HT 6 Our data show that 5-HT 6 receptors are expressed in the rat and porcine striatum. In agreement with our results, 5-HT-mediated stimulation of adenylyl cyclase activity with a 5-HT 6 receptor-like pharmacological profile has been observed in porcine striatal membrane preparations (Schoeffter and Waeber, 1994) and mouse striatal neurons in primary culture (Sebben et al., 1994) . Sebben et al. (1994) (Sebben et al., 1994) was approximately 10-fold lower than the value we observed in membranes prepared from freshly dissected rat and porcine striatum (175 and 130 fmol/mg protein, respectively). This may indicate that the expression of 5-HT 6 receptors actually diminishes during primary culture or that species differences exist in the levels of 5-HT 6 receptor expression. ]Ro 63-0563 will therefore be a useful tool to determine the expression level of 5-HT 6 receptors in different brain regions. In addition, our data support the results of studies using antisense oligonucleotides (Bourson et al., 1995; Sleight et al., 1996) and the 5-HT 6 receptor selective antagonist Ro 04 -6790 (Sleight et al., 1998) that first suggested the presence of functional 5-HT 6 receptors in the rat brain. Indeed, given the previously reported data from our group (Bourson et al., 1995; Sleight et al., 1996 Sleight et al., , 1998 and the data reported here, we feel justified in abandoning lower case letters for 5-HT 6 receptor nomenclature. 
